The deubiquitinating enzyme USP4 regulates BRCA1 stability and function.


Journal

NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891

Informations de publication

Date de publication:
11 May 2024
Historique:
received: 24 06 2023
accepted: 01 05 2024
medline: 12 5 2024
pubmed: 12 5 2024
entrez: 11 5 2024
Statut: epublish

Résumé

BRCA1 plays a suppressive role in breast tumorigenesis. Ubiquitin-dependent degradation is a common mechanism that regulates BRCA1 protein stability, and several ubiquitin ligases involved have been identified. However, the deubiquitinating enzyme for BRCA1 remains less defined. Here, we report that the deubiquitinase USP4 interacts with, deubiquitinates and stabilizes BRCA1, maintaining the protein level of BRCA1. USP4 knockdown results in a decreased BRCA1 protein level, impairment in homologous recombination mediated double-stranded break repair, and increased genome instability, and confers resistance to DNA damage-inducing agents and PARP inhibitors. Ectopic expression of USP4 stabilizes BRCA1 and reverse the effects caused by USP4 knockdown. Moreover, USP4 is low expressed in human breast cancer tissues and its low expression correlates with poorer survival of patients. Furthermore, we identified several loss-of-function mutations of USP4 in human gynecological cancers, the catalytic activity of which or their interaction with BRCA1 is disrupted. Together, we reveal that USP4 is a deubiquitinase for BRCA1. USP4 positively regulates the stability and function of BRCA1 through de-ubiquitination, and plays important role in the suppression of breast cancer.

Identifiants

pubmed: 38734703
doi: 10.1038/s41523-024-00641-7
pii: 10.1038/s41523-024-00641-7
doi:

Types de publication

Journal Article

Langues

eng

Pagination

35

Subventions

Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 82172924
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 81972477
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 81772953
Organisme : National Science Foundation of China | Major Research Plan
ID : 2017YFA0503900

Informations de copyright

© 2024. The Author(s).

Références

Miki, Y. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66–71 (1994).
doi: 10.1126/science.7545954 pubmed: 7545954
Kwong, A. et al. Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian counties. J. Med. Genet. 53, 15–23 (2016).
pubmed: 26187060 doi: 10.1136/jmedgenet-2015-103132
Baldassarre, G. et al. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol. Cell Biol. 23, 2225–2238 (2003).
pubmed: 12640109 pmcid: 150734 doi: 10.1128/MCB.23.7.2225-2238.2003
Zheng, W. et al. Reduction of BRCA1 expression in sporadic ovarian cancer. Gynecol. Oncol. 76, 294–300 (2000).
pubmed: 10684699 doi: 10.1006/gyno.1999.5664
Taylor, J. et al. An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers. Int. J. Cancer 79, 334–342 (1998).
pubmed: 9699523 doi: 10.1002/(SICI)1097-0215(19980821)79:4<334::AID-IJC5>3.0.CO;2-W
Bochar, D. A. et al. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 102, 257–265 (2000).
pubmed: 10943845 doi: 10.1016/S0092-8674(00)00030-1
Takaoka, M. & Miki, Y. BRCA1 gene: function and deficiency. Int. J. Clin. Oncol. 23, 36–44 (2018).
pubmed: 28884397 doi: 10.1007/s10147-017-1182-2
Venkitaraman, A. R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108, 171–182 (2002).
pubmed: 11832208 doi: 10.1016/S0092-8674(02)00615-3
Yoshida, K. & Miki, Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 95, 866–871 (2004).
pubmed: 15546503 doi: 10.1111/j.1349-7006.2004.tb02195.x
Zhang, F. et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr. Biol. 19, 524–529 (2009).
pubmed: 19268590 pmcid: 2750839 doi: 10.1016/j.cub.2009.02.018
Mullan, P. B., Quinn, J. E. & Harkin, D. P. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 25, 5854–5863 (2006).
pubmed: 16998500 doi: 10.1038/sj.onc.1209872
Somasundaram, K. Breast cancer gene 1 (BRCA1): role in cell cycle regulation and DNA repair–perhaps through transcription. J. Cell Biochem. 88, 1084–1091 (2003).
pubmed: 12647291 doi: 10.1002/jcb.10469
Mallery, D. L., Vandenberg, C. J. & Hiom, K. Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains. EMBO J. 21, 6755–6762 (2002).
pubmed: 12485996 pmcid: 139111 doi: 10.1093/emboj/cdf691
Deng, Y. et al. Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1. Oncogene 29, 6603–6608 (2010).
pubmed: 20818429 pmcid: 3081720 doi: 10.1038/onc.2010.406
Deng, Y. et al. Transcriptional down-regulation of Brca1 and E-cadherin by CtBP1 in breast cancer. Mol Carcinog. 51, 500–507 (2012).
pubmed: 21681822 doi: 10.1002/mc.20813
De Siervi, A. et al. Transcriptional autoregulation by BRCA1. Cancer Res. 70, 532–542 (2010).
pubmed: 20068145 pmcid: 2952428 doi: 10.1158/0008-5472.CAN-09-1477
Wang, A., Schneider-Broussard, R., Kumar, A. P., MacLeod, M. C. & Johnson, D. G. Regulation of BRCA1 expression by the Rb-E2F pathway. J. Biol. Chem. 275, 4532–4536 (2000).
pubmed: 10660629 doi: 10.1074/jbc.275.6.4532
Korlimarla, A. et al. Identification of BRCA1 deficiency using multi-analyte estimation of BRCA1 and its repressors in FFPE tumor samples from patients with triple negative breast cancer. PLoS One 11, e0153113 (2016).
pubmed: 27077368 pmcid: 4831669 doi: 10.1371/journal.pone.0153113
Wu, W. et al. HERC2 is an E3 ligase that targets BRCA1 for degradation. Cancer Res. 70, 6384–6392 (2010).
pubmed: 20631078 doi: 10.1158/0008-5472.CAN-10-1304
Lu, Y. et al. The F-box protein FBXO44 mediates BRCA1 ubiquitination and degradation. J. Biol. Chem. 287, 41014–41022 (2012).
pubmed: 23086937 pmcid: 3510804 doi: 10.1074/jbc.M112.407106
Wang, X. et al. HUWE1 interacts with BRCA1 and promotes its degradation in the ubiquitin–proteasome pathway. Biochem. Biophys. Res. Commun. 444, 290–295 (2014).
pubmed: 24342616 doi: 10.1016/j.bbrc.2013.12.053
Liu, F. et al. CRL4-DCAF8L1 regulates BRCA1 and BARD1 protein stability. Int. J. Biol. Sci. 18, 1434–1450 (2022).
pubmed: 35280675 pmcid: 8898372 doi: 10.7150/ijbs.57178
Peng, Y. et al. TUSC4 functions as a tumor suppressor by regulating BRCA1 stability. Cancer Res. 75, 378–386 (2015).
pubmed: 25480944 doi: 10.1158/0008-5472.CAN-14-2315
Kim, S., Jin, H., Seo, H.-R., Lee, H. J. & Lee, Y.-S. Regulating BRCA1 protein stability by cathepsin S-mediated ubiquitin degradation. Cell Death Differ 26, 812–825 (2019).
pubmed: 30006610 doi: 10.1038/s41418-018-0153-0
Clague, M. J., Urbé, S. & Komander, D. Breaking the chains: deubiquitylating enzyme specificity begets function. Nat. Rev. Mol. Cell Biol. 20, 338–352 (2019).
pubmed: 30733604 doi: 10.1038/s41580-019-0099-1
Li, W. et al. Deubiquitinase USP20 promotes breast cancer metastasis by stabilizing SNAI2. Genes Dev. 34, 1310–1315 (2020).
pubmed: 32943575 pmcid: 7528704 doi: 10.1101/gad.339804.120
Abdul Rehman, S. A. et al. MINDY-1 is a member of an evolutionarily conserved and structurally distinct new family of deubiquitinating enzymes. Mol. Cell 63, 146–155 (2016).
pubmed: 27292798 pmcid: 4942677 doi: 10.1016/j.molcel.2016.05.009
Li, Y. & Yuan, J. Role of deubiquitinating enzymes in DNA double-strand break repair. J. Zhejiang Univ. Sci. B 22, 63–72 (2021).
pubmed: 33448188 pmcid: 7818009 doi: 10.1631/jzus.B2000309
Kee, Y. & Huang, T. T. Role of deubiquitinating enzymes in DNA repair. Mol. Cell Biol. 36, 524–544 (2016).
pubmed: 26644404 pmcid: 4751696 doi: 10.1128/MCB.00847-15
Lu, Q., Zhang, F.-L., Lu, D.-Y., Shao, Z.-M. & Li, D.-Q. USP9X stabilizes BRCA1 and confers resistance to DNA-damaging agents in human cancer cells. Cancer Med. 8, 6730–6740 (2019).
pubmed: 31512408 pmcid: 6825982 doi: 10.1002/cam4.2528
Liu, H. et al. The deubiquitylating enzyme USP4 cooperates with CtIP in DNA double-strand break end resection. Cell Rep. 13, 93–107 (2015).
Shao, G. et al. The Rap80-BRCC36 de-ubiquitinating enzyme complex antagonizes RNF8-Ubc13-dependent ubiquitination events at DNA double strand breaks. Proc. Natl. Acad. Sci. USA 106, 3166–3171 (2009).
pubmed: 19202061 pmcid: 2651241 doi: 10.1073/pnas.0807485106
Yu, H. et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc. Natl. Acad. Sci. USA 111, 285–290 (2014).
pubmed: 24347639 doi: 10.1073/pnas.1309085110
Jensen, D. E. et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16, 1097–1112 (1998).
pubmed: 9528852 doi: 10.1038/sj.onc.1201861
Nishikawa, H. et al. BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res. 69, 111–119 (2009).
pubmed: 19117993 doi: 10.1158/0008-5472.CAN-08-3355
Uckelmann, M. et al. USP48 restrains resection by site-specific cleavage of the BRCA1 ubiquitin mark from H2A. Nat. Commun. 9, 229 (2018).
pubmed: 29335415 pmcid: 5768779 doi: 10.1038/s41467-017-02653-3
Typas, D. et al. The de-ubiquitylating enzymes USP26 and USP37 regulate homologous recombination by counteracting RAP80. Nucleic Acids Res. 43, 6919–6933 (2015).
pubmed: 26101254 pmcid: 4538816 doi: 10.1093/nar/gkv613
Li, Y. et al. USP13 regulates the RAP80-BRCA1 complex dependent DNA damage response. Nat. Commun. 8, 15752 (2017).
pubmed: 28569838 pmcid: 5461494 doi: 10.1038/ncomms15752
Kim, H., Chen, J. & Yu, X. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 316, 1202–1205 (2007).
pubmed: 17525342 doi: 10.1126/science.1139621
O’Dea, R. & Santocanale, C. Non-canonical regulation of homologous recombination DNA repair by the USP9X deubiquitylase. J. Cell Sci. 133, jcs233437 (2020).
Zhang, X., Berger, F. G., Yang, J. & Lu, X. USP4 inhibits p53 through deubiquitinating and stabilizing ARF-BP1. EMBO J. 30, 2177–2189 (2011).
pubmed: 21522127 pmcid: 3117646 doi: 10.1038/emboj.2011.125
Zhao, B., Schlesiger, C., Masucci, M. G. & Lindsten, K. The ubiquitin specific protease 4 (USP4) is a new player in the Wnt signalling pathway. J. Cell Mol. Med. 13, 1886–1895 (2009).
pubmed: 20141612 pmcid: 9181360 doi: 10.1111/j.1582-4934.2008.00682.x
Zhang, L. et al. USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor. Nat. Cell Biol. 14, 717–726 (2012).
pubmed: 22706160 doi: 10.1038/ncb2522
Zhang, J. et al. The regulation of TGF-β/SMAD signaling by protein deubiquitination. Protein Cell 5, 503–517 (2014).
pubmed: 24756567 pmcid: 4085288 doi: 10.1007/s13238-014-0058-8
Xiao, N. et al. Ubiquitin-specific protease 4 (USP4) targets TRAF2 and TRAF6 for deubiquitination and inhibits TNFα-induced cancer cell migration. Biochem. J. 441, 979–986 (2012).
pubmed: 22029577 doi: 10.1042/BJ20111358
Fan, Y. H. et al. USP4 targets TAK1 to downregulate TNFα-induced NF-κB activation. Cell Death Differ. 18, 1547–1560 (2011).
pubmed: 21331078 pmcid: 3136563 doi: 10.1038/cdd.2011.11
Wijnhoven, P. et al. USP4 auto-deubiquitylation promotes homologous recombination. Mol. Cell 60, 362–373 (2015).
pubmed: 26455393 pmcid: 4643306 doi: 10.1016/j.molcel.2015.09.019
Song, E. J. et al. The Prp19 complex and the Usp4Sart3 deubiquitinating enzyme control reversible ubiquitination at the spliceosome. Genes Dev. 24, 1434–1447 (2010).
pubmed: 20595234 pmcid: 2895201 doi: 10.1101/gad.1925010
Yang, J. et al. Cutting edge: ubiquitin-specific protease 4 promotes Th17 cell function under inflammation by deubiquitinating and stabilizing RORgammat. J. Immunol. 194, 4094–4097 (2015).
pubmed: 25821221 doi: 10.4049/jimmunol.1401451
Narod, S. A. & Foulkes, W. D. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 4, 665–676 (2004).
pubmed: 15343273 doi: 10.1038/nrc1431
Smith, S. A., Easton, D. F., Evans, D. G. & Ponder, B. A. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat. Genet. 2, 128–131 (1992).
pubmed: 1303261 doi: 10.1038/ng1092-128
Thompson, M. E., Jensen, R. A., Obermiller, P. S., Page, D. L. & Holt, J. T. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat. Genet. 9, 444–450 (1995).
pubmed: 7795653 doi: 10.1038/ng0495-444
Yoshikawa, K. et al. Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. Clin. Cancer Res. 5, 1249–1261 (1999).
pubmed: 10389907
Liu, F. H. et al. CRL4-DCAF8L1 regulates BRCA1 and BARD1 protein stability. Int. J. Biol. Sci. 18, 1434–1450 (2022).
pubmed: 35280675 pmcid: 8898372 doi: 10.7150/ijbs.57178
Choudhury, A. D., Xu, H. & Baer, R. Ubiquitination and proteasomal degradation of the BRCA1 tumor suppressor is regulated during cell cycle progression. J. Biol. Chem. 279, 33909–33918 (2004).
pubmed: 15166217 doi: 10.1074/jbc.M403646200
Chen, Y. et al. Aberrant subcellular localization of BRCA1 in breast cancer. Science 270, 789–791 (1995).
pubmed: 7481765 doi: 10.1126/science.270.5237.789

Auteurs

Xueyuan Guo (X)

Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.

Yanfang Ma (Y)

Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.

Ting Zhang (T)

Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.

Runyu Liu (R)

Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.

Fen Chang (F)

Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.

Xingyue Yan (X)

Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.

Tianyun Yu (T)

Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.

Pengfei Wu (P)

Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.

Qin Li (Q)

Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.

Luzheng Xu (L)

Center of Medical and Health Analysis, Peking University Health Science Center, Beijing, 100191, China.

Junyi Duan (J)

Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.

Li Li (L)

Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.

Yanrong Su (Y)

The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA, 19111, USA.

Genze Shao (G)

Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China. gzshao@bjmu.edu.cn.

Classifications MeSH